{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T23:04:46Z","timestamp":1792623886754,"version":"4.5.0"},"reference-count":49,"publisher":"BMJ","issue":"3","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"unspecified","delay-in-days":6,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100019353","name":"Belgian Health Care Knowledge Centre","doi-asserted-by":"publisher","award":["CB-1602"],"award-info":[{"award-number":["CB-1602"]}],"id":[{"id":"10.13039\/501100019353","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To investigate if patients with early rheumatoid arthritis responding insufficiently to initial methotrexate (MTX) and bridging glucocorticoids (GCs) could benefit from early but temporary etanercept introduction as a second remission-induction attempt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      CareRA2020 (\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03649061\">NCT03649061<\/jats:ext-link>\n                      ) was a 2-year, open-label, multicentre, pragmatic randomised controlled trial. Treatment-na\u00efve patients started MTX and GC bridging (COBRA-Slim: CS). Within a time window from week (W) 8 until W32, early insufficient responders (28-joint Disease Activity Score \u2013 C-reactive Protein (DAS28-CRP) &gt;3.2 between W8 and W32 or \u22652.6 at W32) were randomised to a Standard-CS strategy (adding leflunomide first) or Bio-induction-CS strategy (adding etanercept for 24 weeks). Additional treatment adaptations followed the treat-to-target principle. Longitudinal disease activity (DAS28-CRP) over 104 weeks (primary outcome), achievement of DAS28-CRP &lt;2.6 28 weeks after randomisation, and biologic or targeted synthetic disease-modifying antirheumatic drug (b\/tsDMARD) use at W104 were compared between randomisation groups.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Following CS treatment, 142 patients were early responders; 55 early insufficient responders received Standard-CS and 55 Bio-induction-CS. Superiority of Bio-induction-CS over Standard-CS could not be demonstrated (\u00df=\u22120.204, (95% CI \u20130.486 to 0.078), p=0.157) for the primary outcome. More patients on Bio-induction-CS achieved DAS28-CRP &lt;2.6 at 28 weeks after randomisation (59% (95% CI 44% to 72%) vs 44% (95% CI 31% to 59%) in Standard-CS) and they were treated less frequently with b\/tsDMARDs at W104 (19\/55, 35%) compared with Standard-CS (29\/55, 53%).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Half of the patients responded well to initial COBRA-Slim induction therapy. In early insufficient responders, adding etanercept for 6 months did not improve disease control over 104 weeks versus adding leflunomide first. However, temporary introduction of etanercept resulted in improved disease control early after randomisation and less patients on b\/tsDMARDs at W104.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"clintrialgov\" xlink:href=\"NCT03649061\">NCT03649061<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CTR pilot approval Belgium<\/jats:title>\n                    <jats:p>S59474, EudraCT number: 2017-004054-41.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/rmdopen-2024-004535","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T03:55:15Z","timestamp":1723089315000},"page":"e004535","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Effectiveness of methotrexate and bridging glucocorticoids with or without early introduction of a 6-month course of etanercept in early RA: results of the 2-year, pragmatic, randomised CareRA2020 trial"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct03649061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03649061","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03649061","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4330-1447","authenticated-orcid":false,"given":"Delphine","family":"Bertrand","sequence":"first","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Joly","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Neerinckx","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Cliniques universitaires Saint-Luc, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Lenaerts","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"},{"name":"Reuma Instituut, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rik","family":"Joos","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, ZNA Jan Palfijn, Merksem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristof","family":"Thevissen","sequence":"additional","affiliation":[{"name":"Reumacentrum, Genk, Belgium"},{"name":"Department of Rheumatology, Ziekenhuis Oost-Limburg, Genk, Limburg, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Zwaenepoel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, OLV Ziekenhuis, Aalst, Oost-Vlaanderen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vanhoof","sequence":"additional","affiliation":[{"name":"ReumaClinic, Genk, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvana","family":"Di Romana","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU Saint-Pierre, Bruxelles, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veerle","family":"Taelman","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Regionaal Ziekenhuis Heilig Hart Leuven, Leuven, Vlaams Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Els","family":"Van Essche","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Imeldaziekenhuis, Bonheiden, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luk","family":"Corluy","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AZ Herentals, Herentals, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clio","family":"Ribbens","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU de Li\u00e8ge, Li\u00e8ge, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Vanden Berghe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Grand H\u00f4pital de Charleroi Site Saint-Joseph, Gilly, Hainaut, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mieke","family":"Devinck","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AZ Sint-Lucas Brugge, Brugge, West-Vlaanderen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9162-9717","authenticated-orcid":false,"given":"Sofia","family":"Ajeganova","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZ Brussel, Brussel, Belgium"},{"name":"Department of Medicine, Karolinska Institute, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Durnez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AZ Jan Portaels, Vilvoorde, Vlaams Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Boutsen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, CHU UCL Namur, Yvoir, Namur, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Margaux","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, H\u00f4pital Erasme, Bruxelles, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Peene","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, AZ Sint-Jan Brugge AV, Brugge, West-Vlaanderen, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Van Offel","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, UZA, Edegem, Antwerp, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6073-7635","authenticated-orcid":false,"given":"Micha\u00ebl","family":"Doumen","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8579-6914","authenticated-orcid":false,"given":"Sofia","family":"Pazmino","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Chronic Diseases and Metabolism, Clinical and Experimental Endocrinology, KU Leuven, Leuven, Flanders, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"De Meyst","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myroslava","family":"Kulyk","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Bogomolets National Medical University, Kiiv, Ukraine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelly","family":"Creten","sequence":"additional","affiliation":[{"name":"ReumaNet vzw, Zaventem, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-3073","authenticated-orcid":false,"given":"Ren\u00e9","family":"Westhovens","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0340-3580","authenticated-orcid":false,"given":"Patrick","family":"Verschueren","sequence":"additional","affiliation":[{"name":"Department of Development and Regeneration, Skeletal Biology and Engineering Research Center, KU Leuven, Leuven, Flanders, Belgium"},{"name":"Department of Rheumatology, UZ Leuven, Leuven, Vlaams-Brabant, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"2025090312522781000_10.3.e004535.1","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223356"},{"key":"2025090312522781000_10.3.e004535.2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207524"},{"key":"2025090312522781000_10.3.e004535.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222517"},{"key":"2025090312522781000_10.3.e004535.4","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s13075-021-02651-3","article-title":"Treatment response and several patient-reported outcomes are early determinants of future self-efficacy in rheumatoid arthritis","volume":"23","author":"Doumen","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090312522781000_10.3.e004535.5","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211375"},{"key":"2025090312522781000_10.3.e004535.6","doi-asserted-by":"publisher","DOI":"10.1002\/art.21405"},{"key":"2025090312522781000_10.3.e004535.7","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1093\/rheumatology\/kez213","article-title":"Effectiveness of different combinations of dmards and glucocorticoid bridging in early rheumatoid arthritis: two-year results of carera","volume":"58","author":"Stouten","year":"2019","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312522781000_10.3.e004535.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219825"},{"key":"2025090312522781000_10.3.e004535.9","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-205489"},{"key":"2025090312522781000_10.3.e004535.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203819"},{"key":"2025090312522781000_10.3.e004535.11","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"key":"2025090312522781000_10.3.e004535.12","doi-asserted-by":"publisher","DOI":"10.1002\/art.24169"},{"key":"2025090312522781000_10.3.e004535.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203243"},{"key":"2025090312522781000_10.3.e004535.14","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13075-015-0912-y","article-title":"Two-year results of disease activity score (DAS)-remission-steered treatment strategies aiming at drug-free remission in early arthritis patients (the IMPROVED-study)","volume":"18","author":"Heimans","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025090312522781000_10.3.e004535.15","article-title":"Down-titration and discontinuation strategies of tumour necrosis factor-blocking agents for rheumatoid arthritis in patients with low disease activity","volume":"5","author":"Verhoef","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2025090312522781000_10.3.e004535.16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61751-1"},{"key":"2025090312522781000_10.3.e004535.17","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209212"},{"key":"2025090312522781000_10.3.e004535.18","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.330.7495.843"},{"key":"2025090312522781000_10.3.e004535.19","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.135129"},{"key":"2025090312522781000_10.3.e004535.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.018457"},{"key":"2025090312522781000_10.3.e004535.21","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"2025090312522781000_10.3.e004535.22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312522781000_10.3.e004535.23","doi-asserted-by":"crossref","first-page":"215824401453485","DOI":"10.1177\/2158244014534858","article-title":"Bias in area under the curve for longitudinal clinical trials with missing patient reported outcome data","volume":"4","author":"Bell","year":"2014","journal-title":"SAGE Open"},{"key":"2025090312522781000_10.3.e004535.24","first-page":"261","article-title":"How to read radiographs according to the sharp\/van der heijde method","volume":"27","author":"van der Heijde","year":"2000","journal-title":"J Rheumatol"},{"key":"2025090312522781000_10.3.e004535.25","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew030"},{"key":"2025090312522781000_10.3.e004535.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.10181"},{"key":"2025090312522781000_10.3.e004535.27","doi-asserted-by":"publisher","DOI":"10.2307\/2289225"},{"key":"2025090312522781000_10.3.e004535.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1303006"},{"key":"2025090312522781000_10.3.e004535.29","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1093\/rheumatology\/kep261","article-title":"Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial","volume":"48","author":"Soubrier","year":"2009","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312522781000_10.3.e004535.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202735"},{"key":"2025090312522781000_10.3.e004535.31","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216539"},{"key":"2025090312522781000_10.3.e004535.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60944-2"},{"key":"2025090312522781000_10.3.e004535.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.068296"},{"key":"2025090312522781000_10.3.e004535.34","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200945"},{"key":"2025090312522781000_10.3.e004535.35","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1002\/acr.23900","article-title":"Patient\u2010Reported outcome data from an early rheumatoid arthritis trial: opportunities for broadening the scope of treating to target","volume":"71","author":"Van der Elst","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312522781000_10.3.e004535.36","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220750"},{"key":"2025090312522781000_10.3.e004535.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00380-9"},{"key":"2025090312522781000_10.3.e004535.38","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)30363-4"},{"key":"2025090312522781000_10.3.e004535.39","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1136\/annrheumdis-2019-215304","article-title":"Initiating tocilizumab, with or without methotrexate, compared with starting methotrexate with prednisone within step-up treatment strategies in early rheumatoid arthritis: an indirect comparison of effectiveness and safety of the U-act-early and CAMERA-II treat-to-target trials","volume":"78","author":"Verhoeven","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2025090312522781000_10.3.e004535.40","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1002\/acr.23284","article-title":"Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice\u2010based call for A paradigm change","volume":"70","author":"Ferreira","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090312522781000_10.3.e004535.41","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1093\/rheumatology\/keac213","article-title":"New indicator for discordance between patient-reported and traditional disease activity outcomes in patients with early rheumatoid arthritis","volume":"62","author":"Pazmino","year":"2022","journal-title":"Rheumatology (Sunnyvale)"},{"key":"2025090312522781000_10.3.e004535.42","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200038"},{"key":"2025090312522781000_10.3.e004535.43","doi-asserted-by":"crossref","unstructured":"Heckert SL , Maassen JM , Nevins I , et al . Long-term clinical outcomes in early rheumatoid arthritis that was treated-to-target in the best and IMPROVED studies. Rheumatology (Sunnyvale) 2024. doi:10.1093\/rheumatology\/keae212","DOI":"10.1093\/rheumatology\/keae212"},{"key":"2025090312522781000_10.3.e004535.44","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224116"},{"key":"2025090312522781000_10.3.e004535.45","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224904"},{"key":"2025090312522781000_10.3.e004535.46","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200011303432201"},{"key":"2025090312522781000_10.3.e004535.47","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204788"},{"key":"#cr-split#-2025090312522781000_10.3.e004535.48.1","doi-asserted-by":"crossref","unstructured":"Bertrand D , Joly J , Neerinckx B , et al . OP0129\u2005EFFECTIVENESS of cobra-slim with or without early access to a temporary 6-month course of etanercept in early ra: primary outcome of the 2-year, pragmatic, randomised carera2020 trial. EULAR 2023 European Congress of Rheumatology, 31 May - 3 June. Milan, Italy","DOI":"10.1136\/annrheumdis-2023-eular.2534"},{"key":"#cr-split#-2025090312522781000_10.3.e004535.48.2","doi-asserted-by":"crossref","unstructured":"June 2023 doi:10.1136\/annrheumdis-2023-eular.2534","DOI":"10.1136\/annrheumdis-2023-eular.2534"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2024-004535","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:52:35Z","timestamp":1756929155000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2024-004535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":49,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,8,7]]},"published-print":{"date-parts":[[2024,8]]}},"alternative-id":["10.1136\/rmdopen-2024-004535"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2024-004535","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8]]}}}